万孚生物(300482) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 861,092,255.54, representing a 3.54% increase compared to CNY 831,629,122.23 in the same period last year[16]. - Net profit attributable to shareholders for Q1 2024 was CNY 218,334,248.48, up 7.20% from CNY 203,678,161.27 year-on-year[16]. - The company reported a basic earnings per share of CNY 0.49, up 6.52% from CNY 0.46 in the same period last year[16]. - Net profit for the current period was ¥220,443,620.50, representing a 9.1% increase from ¥202,212,680.82 in the previous period[28]. - The total comprehensive income for the current period was ¥220,857,097.78, up from ¥202,604,008.04 in the previous period[28]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to CNY 113,224,704.67, a 151.07% increase compared to a negative cash flow of CNY -221,701,390.44 in the previous year[16]. - The company reported a net cash inflow from financing activities of CNY 692,085,292.40 for the first quarter, a turnaround from a net outflow of CNY 200,348,519.87 in the same period last year[49]. - Cash and cash equivalents increased by 39.29% to CNY 1,170,447,525.51, primarily due to the proceeds from a private placement[7]. - Cash and cash equivalents at the end of the first quarter reached CNY 1,169,728,156.09, compared to CNY 748,525,744.53 at the end of the previous year, indicating a significant increase of approximately 56.2%[49]. - The company's cash and cash equivalents position remains strong, supporting ongoing operational and strategic initiatives[24]. Assets and Liabilities - Total assets at the end of Q1 2024 reached CNY 6,673,949,590.10, marking a 15.63% increase from CNY 5,771,717,185.26 at the end of the previous year[16]. - Guangzhou Wanfeng Biotechnology Co., Ltd. reported a total liability of CNY 1,149,478,142.84 as of March 31, 2024, a decrease from CNY 1,157,093,084.26 in the previous period[24]. - The company's total equity increased to CNY 5,524,471,447.26 from CNY 4,614,624,101.00, reflecting a growth in shareholder value[24]. - The total number of shares outstanding increased to 471,966,578.00 from 444,515,598.00, indicating a potential increase in market capitalization[24]. - The company's total current assets rose to CNY 4,050,347,276.26, up from CNY 3,233,336,220.02, marking an increase of about 25.3%[40]. Investment and Expenses - The company recorded a significant increase in investment income, which rose by 81.08% to CNY 2,955,606.08 compared to CNY 1,632,214.98 in the previous year[7]. - The company experienced a decrease in financial expenses, which improved by 155.96% to CNY -7,251,461.78, attributed to increased foreign exchange gains[7]. - Research and development expenses increased to ¥105,547,760.15, up from ¥94,403,973.82, indicating a focus on innovation[27]. - The company raised ¥690,599,990.10 from investment activities, indicating strong capital inflow[30]. Shareholder Information - The number of shares held by major shareholders includes Guangzhou Huayin Tianyue Equity Investment Fund Management Co., Ltd. with 49,195,579 shares, representing 11.07% of the total share capital[20]. - The company’s major shareholders, Li Wenmei and Wang Jihua, hold a combined 33.17% of the total shares, with Li owning 22.01% and Wang 11.16%[52].